"Epothilones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).
| Descriptor ID |
D034261
|
| MeSH Number(s) |
D02.540.576.500.984
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Epothilones".
Below are MeSH descriptors whose meaning is more specific than "Epothilones".
This graph shows the total number of publications written about "Epothilones" by people in this website by year, and whether "Epothilones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Epothilones" by people in Profiles.
-
Kelly WK. Epothilones in prostate cancer. Urol Oncol. 2011 Jul-Aug; 29(4):358-65.
-
Fogh S, Machtay M, Werner-Wasik M, Curran WJ, Bonanni R, Axelrod R, Andrews D, Dicker AP. Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys. 2010 Jul 15; 77(4):1009-16.
-
Lee JJ, Kelly WK. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy. Nat Clin Pract Oncol. 2009 Feb; 6(2):85-92.
-
Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008 May; 19(5):977-83.
-
Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007 Aug 01; 110(3):556-63.
-
Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer. 2006 Jan 01; 106(1):58-62.
-
Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005 Mar 01; 23(7):1439-46.
-
O'Neil BH, Goldberg RM. Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can). Semin Oncol. 2005 Feb; 32(1):35-42.
-
Smaletz O, Galsky M, Scher HI, DeLaCruz A, Slovin SF, Morris MJ, Solit DB, Davar U, Schwartz L, Kelly WK. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol. 2003 Oct; 14(10):1518-24.
-
Taraschi TF, Trelka D, Schneider T, Matthews I. Plasmodium falciparum: characterization of organelle migration during merozoite morphogenesis in asexual malaria infections. Exp Parasitol. 1998 Mar; 88(3):184-93.